Oncotarget

Research Perspectives:

Targeting Rb mutant cancers by inactivating TSC2

Jennifer S. Searle, Binghui Li and Wei Du _

PDF  |  How to cite  |  Order a Reprint

Oncotarget. 2010; 1:228-232. https://doi.org/10.18632/oncotarget.130

Metrics: PDF 3339 views  |   ?  


Abstract

Received: July 23, 2010, Accepted: July 25, 2010, Published: July 26, 2010

Retinoblastoma (Rb), a tumor suppressor gene, is inactivated in many types of cancer. However little is known about how the loss of Rb function can be targeted in cancer therapies. We have identified that inactivation of TSC2 in Rb mutant cancer cells will induce a synergistic cell death. The synergistic cell death is due to an increase in cellular stress including, metabolic, ER, and oxidative stress. Therefore, inactivation of TSC2 and chemothereputics that result in induction of cellular stress may be a novel and effective way to treat cancers containing inactivated Rb.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 130